GlassScriptPhysician profile
Esther Ajjarapu
NPI 1952630725
$4,612.72
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $462 · 2021: $937 · 2022: $2,882 · 2023: $296 · 2024: $36.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,174.29 | 2020-2023 | Vraylar |
| Novo Nordisk INC | $581.12 | 2020-2023 | Wegovy |
| Glaxosmithkline, LLC. | $570.63 | 2020-2022 | |
| Lilly USA, LLC | $200.99 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $151.97 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $104.97 | 2020-2023 | |
| Pfizer INC. | $94.14 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $78.15 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.03 | 2021 | |
| Amgen INC. | $58.06 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.77 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $47.58 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.25 | 2022 | |
| Allergan, INC. | $37.87 | 2020 | |
| Astellas Pharma US INC | $36.24 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $36.21 | 2024 | Closurefast |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.97 | 2021 | |
| Acadia Pharmaceuticals INC | $29.80 | 2020 | |
| Alkermes, INC. | $25.72 | 2023 | Lybalvi |
| Janssen Pharmaceuticals, INC | $25.29 | 2021 | |
| Exact Sciences Corporation | $24.08 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $23.68 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $23.50 | 2020-2022 | |
| Inogen, INC. | $21.43 | 2022 | |
| Gilead Sciences, INC. | $18.80 | 2023 | |
| Xeris Pharmaceuticals, INC. | $18.58 | 2023 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $16.28 | 2020 | |
| Currax Pharmaceuticals LLC | $13.43 | 2021 | |
| Dexcom, INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Ajjarapu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.